Amy PJ Chen, MD

Medical oncology/Hematology fellow. Physician Scientist

[Mark Yarchoan @MarkYarchoan]

Disappointing news in #HCC: the much-anticipated Phase 3 IMbrave152 trial (atezo/bev ± tiragolumab) has quietly read out negative

https://t.co/3oAdrGIiwO

[Jun Gong, MD @jgong15]

Today is #WorldCancerDay thank you @KTLA for this interview & raising cancer awareness @LuParker @glenwalkerktla

@CSCancerCenter @OncoAlert @Larvol @OPENoncology @oncodaily @CParkMD @medicalwatchBC @MOASC_Office @OncoReporte @LinksCancer @OncBrothers

https://t.co/R5VaPDMKPU

[Arndt Vogel @ArndtVogel]

Pathological response following neoadjuvant immune checkpoint inhibitors in HCC: a cross-trial, patient-level analysis
@TheLancetOncol
https://t.co/0vZEXh9Qxj
👉111 pts, 1.4 mo neoadj. 💊
👉MPR: 32%, PCR 18%
👉Best threshold 90%
🧐Neoadj ICI is the way to go
@ILCAnews @EASLedu @myESMO #livertwitter

[Amy PJ Chen, MD @AmyPJChen1]

[ILCA 2024]
Grateful to attend this very informative meeting and to listen to the experts’ discussions. Lots of discussions in the intermediate stage HCC space around Emerald-01 and LEAP-012.

[Amy PJ Chen, MD @AmyPJChen1]

[AACR/ASCO Methods in Clinical Cancer Research Workshop]
7/28-8/3/2024
Amazing learning and networking experience with the selected fellows and junior faculty all over the country.

[FOX Soccer @FOXSoccer]

"This is my dream. I'm speechless."

An emotional Emi Martinez describes his emotions after Argentina wins the 2022 FIFA World Cup 🇦🇷

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

New in @Nature from @SohrabShah, @sajraparicio & team: How cell-to-cell structural variation contributes to the origins of phenotypic and evolutionary diversity in triple-negative #BreastCancer and high-grade serous #OvarianCancer. https://t.co/QIwJj1MGfJ

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

MSK physician-scientist @CharlesSawyers & computational biologist @dana_peer led a team that shed new light on mechanisms by which prostate cancer cells can transform and resist hormone therapy, opening the door to new clinical approaches. Find out more. https://t.co/vhvpDVm7IU

[Laver Cup @LaverCup]

If there's one thing you watch today, make it this.

#LaverCup | @rogerfederer

[ChainReaper @_Chain_Reaper_]

See our latest work in rectal cancer. Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer | Nature Medicine https://t.co/6PKEUlifhX

[Claudia Cardone @clacardone]

This waterfall plot made me emotional

Outstanding presentation of
#NICHE trial results

Congrats to @MyriamChalabi
#ESMO22

[Alex Ritter, PhD @AlexRitterPhD]

Killer T cells are beautiful! This high resolution/rapid acquisition video of a T cell attacking a lymphoma cancer cell was captured on a specialized Lattice Light Sheet microscope with the help of my wonderful collaborators @HHMIJanelia. See more details in the thread below.

[Annals of Oncology @Annals_Oncology]

In the 1st-line setting of advanced NSCLC 🫁, anti-PD(L)1 monotherapy has regulatory approval in tumors with high PDL1 expression (≥50%) while the chemo + IO combo is approved irrespective of PDL1 expression.

👇

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

It’s the last week of #2021! To round out the year, we’re sharing 10 clinical advances our amazing scientists and doctors made to improve the treatment of #cancer this year.
https://t.co/wefzOIoqCJ

[Carlos Fernandez de Larrea @fdezdelarrea]

First-in-Class Trial MCARH109, a GPRC5D Targeted CAR T Cell Therapy in Patients with Refractory Multiple Myeloma. Great results, even for patients treated previously with antiBCMA therapies. Amazing job Sham and @ESmithMDPhD GPRC5D rocks! @sloan_kettering #ASH21 @ASH_hematology

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

🚨 #ASH21 News - Results from the first-ever trial for a new class of #leukemia drugs called menin inhibitors are encouraging. Read more: https://t.co/0mkiFH1uhz

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

This year, MSK’S own @YJanjigianMD led not one, but two clinical trials resulting in FDA authorizations for two treatments that can give hope to some gastric and esophageal #cancer patients. Read the full story here. #StomachCancerAwarenessMonth
https://t.co/ifFSGirsiO

[Hepatology Communications @HepCommJournal]

🔥The genomics of a resected #HCC can be used to predict recurrence following liver transplant 🔥

👉https://t.co/VXacxNrkyH

#livercancer #hepatocellularcarcinoma #livertwitter #VisualAbstract #openaccess

[Liver Transplantation Journal (LTxJournal) @LTxJournal]

Circulating Tumor Cell‐Based mRNA Scoring System for Prognostication of Hepatocellular Carcinoma ‐ Translating HCC Tissue‐based mRNA Profiling into a Non‐invasive Setting from @VatcheAgopianMD and colleagues. https://t.co/gvjGHLEc2X

[Yelena Y. Janjigian MD @YJanjigianMD]

I got to spend the week with this excellent team of residents rounding @sloan_kettering. Up next they get to round with DOM Chair. Thank you for covering the service this weekend Deb Schrag @debschrag. @MSK_MedChiefs @MSKEducation